Table 3

Sensitivity to change of ESSDAI and ClinESSDAI in patients with primary Sjögren's syndrome treated with belimumab and rituximab

ESSDAIClinESSDAI
Belimumab trial N=30
Baseline value
 Median (IQR)7 (3–12)6.5 (2–12)
 Mean±SD8.80±7.398.33±7.88
SRM (95% CI)
 Week 12−0.89 (−1.22 to −0.63)−0.84 (−1.15 to −0.55)
 Week 28−0.64 (−1.36 to −0.18)−0.53 (−1.16 to −0.08)
Rituximab trial N=28
 Baseline value
 Median (IQR)7.5 (4–10)6 (4–10)
 Mean±SD8.96±4.487.68±5.02
 SRM (95% CI)
  Week 16−1.24 (−1.80 to −0.81)−1.07 (−1.63 to −0.68)
  Week 24−0.98 (−1.43 to −0.66)−0.90 (−1.33 to −0.60)
  • ClinESSDAI, Clinical ESSDAI (ie. without the biological domain); ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; EULAR, European League Against Rheumatism; SRM, standardised response mean.